Nursing homes should prepare to meet antipsychotic reduction goals, quality chief says

Share this article:

The American Health Care Association's David Gifford, M.D., is offering tips for nursing homes looking to meet regulator and trade group deadlines for reducing antipsychotics use.

Quality initiatives launched by the Centers for Medicare & Medicaid Services and AHCA have targeted Dec. 31 as the deadline for long-term care facilities to cut their antipsychotic use by 15%. Gifford, AHCA's senior vice president of quality and regulatory affairs, told McKnight's Editor Jim Berklan that facilities can get this process started with residents who don't need these medications on a daily basis.

“Certainly, initially, they can target individuals who are on PRN or as- needed doses or very low doses,” Gifford said. “Literature suggests you can safely withdraw people from that medication. And the vast majority do not need to have it restarted.”

Gifford also encouraged member facilities to apply for the association's National Quality Award Program. The deadline for applications is Nov. 1. The awards are based on the criteria for the Baldridge Performance Excellence Program.

Click on the video posted above of Berklan's interview with Gifford at the AHCA annual conference in Tampa earlier this week.

Share this article:

More in News

Large hepatitis outbreak reaches 47 cases, podiatry company denies ManorCare's charges

The number of people infected in an infamous North Dakota Hepatitis C outbreak has risen, state health officials say.

National Quality Forum supports quality measures in bill to standardize post-acute assessments

National Quality Forum supports quality measures in bill ...

The National Quality Forum has come out in strong support of a proposed standardized quality measures, such as skin integrity, across different types of post-acute care settings. Uniform assessments are ...

CMS changes mind on hospice drugs

The Centers for Medicaid & Medicare Services has revised guidance on authorization of hospice drugs for those under Medicare Advantage and Part D plans, according to a new memo.